Unlicensed Cannabis Products in New York Contaminated with Harmful Substances

Dec.02.2022
Unlicensed Cannabis Products in New York Contaminated with Harmful Substances
An industry report found illegal marijuana sales in New York contain harmful bacteria, heavy metals, and toxic pesticides.

A report released on Wednesday reveals that some marijuana products sold in unlicensed stores in New York are not only illegal but contaminated with harmful bacteria, heavy metals, and toxic pesticides.


The association conducted laboratory tests on smokable cannabis, edible candies, and vaporizers purchased from 20 tobacco shops and pharmacies. They found eight different contaminants, including E. coli, salmonella, nickel, and lead, which are prohibited. According to a report from the New York Medical Marijuana Industry Association, a state trade organization, the investigation also revealed that some products had incorrect labeling of their strength.


The association represents licensed healthcare pharmacy operators in New York. It stated that the investigation's results highlight the concerns of elected officials and regulatory agencies regarding the danger posed by the reckless growth of retail stores in the state, which falsely claim that their products are legal.


At present, legal sales of marijuana in New York are limited to patients of 38 medical dispensaries operated by the association. However, prior to the release of this report, regulatory authorities granted licenses to 36 retail dispensaries in the state's first batch of approvals. The regulatory authorities stated that legal sales of recreational marijuana will begin in December.


The industry association stated in its report that "just as the imperial government was preparing to achieve this important goal, new illegal operators have emerged, seizing the tail of the highly respected legacy market, endangering public health and safety as well as the long-term success of legitimate operators.


For years, medical pharmacy operators have been frustrated by their exclusion from the New York retail market due to the prevalence of unlawful storefronts operating without regulation or repercussions. The report aims to pressure authorities to restrict illegal sales, as the healthcare industry seeks modifications to proposed regulations that would require them to pay at least $3 million to enter the retail market.


According to laboratory results, these tests were authorized by Curaleaf, a national chain with four locations in New York, currently facing fines, lawsuits, and product recalls in at least five states as well as license revocations in Oregon.


In Kura Sushi's statement, it defended the reputation of the company by pointing out that the suspension in Oregon is the first time in the 12 years of operation of the chain. A senior female spokesperson stated that this incident involves mislabeled products, and the discovery proves that supervision of the industry is working and regulatory agencies are also taking note of the company's cooperation.


She said that illegal markets in New York or any other state do not have this type of regulatory mechanism.


A newspaper has obtained a report from a basic laboratory test, but no independent verification of any testing results has been completed. Experts advise caution when interpreting these findings, noting that bacteria die when exposed to smoke and some metals and pesticides are considered safe in low amounts. Officials from the city government and cannabis regulatory agencies have stated that they are reviewing the report.


Overall, tests revealed that 16 out of 40 products were found to contain pollutants. Nine products contained tetrahydrocannabinol (THC), the intoxicating compound found in marijuana, at levels lower than what was advertised on their labels. However, analysis showed that one type of gummy candy claimed to have 100 milligrams of THC per piece on its label, but actually contained twice that amount.


The most common pollutants found in cannabis products are Escherichia coli and Salmonella, which were detected in nine different items, particularly loose bud and pre-rolled joints. National regulations prohibit the sale of cannabis products contaminated with these bacteria to consumers. Both types of bacteria can cause infections, often resulting in symptoms such as diarrhea, vomiting, fever, and cramps. In severe cases, they can be life-threatening.


The CEO of Talon Analytical, a laboratory licensed by the state, Michael Bianco, has stated that the tested products do not meet the standards set in New York. The company has tested illegal products for their clients, which are mostly medical marijuana companies.


The spokesperson for the Cannabis Control Office, Aaron Ghitelman, stated that the report confirms officials' long-standing claims about the risks of unregulated products and the necessity of shutting down unlicensed storefronts. The agency's governing board passed regulation last week denying licenses to individuals who sell marijuana in unlicensed storefronts or vehicles, or in any other way falsely claiming to be operating legally.


The office is currently involved in a cross-departmental joint law enforcement pilot with the city. Mayor Eric Adams has stated that this initiative has resulted in the confiscation of over 100,000 items and the issuance of 300 civil and criminal violations.


Officials did not indicate whether they will take action against any specific companies that were involved in the sale of tested products mentioned in the report.


2FIRSTS will continue to provide updates on this issue, with further information available on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
 $20 Million, a Permanent Injunction and Distributor Controls: Posh Deal Tightens Illinois Vape Compliance
$20 Million, a Permanent Injunction and Distributor Controls: Posh Deal Tightens Illinois Vape Compliance
An Illinois court ordered three companies tied to Posh vapes to pay $20 million and permanently restricted the sale, marketing and distribution in Illinois of products lacking required FDA authorization. The consent order also imposes downstream distributor controls, age-verification measures and social-media marketing limits, creating a new state-level compliance benchmark for disposable vape businesses.
Regulations
Aug.05
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20